Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability
线粒体 Sirt3 缺失、MnSOD 活性降低和 IR 诱导的基因组不稳定
基本信息
- 批准号:9440346
- 负责人:
- 金额:$ 36.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-07 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): One idea of personalized cancer therapy is to identify specific subgroups of cancer patients that will benefit from specific therapeutic strategies. Recently, the NCI has proposed a new research emphasis to design rigorous and innovative research strategies to solve specific problems and paradoxes in cancer research. This research proposal addresses an NCI emphasis: that is how do the proteins that direct life span, at least in some part, affect the molecular mechanisms of cancer development. In addition, can a greater understanding of the mechanisms that direct aging be used to enhance the prevention and/or treatment of cancer? In this regard, it is proposed that the CLOCK/NAD+/SIRT3 axis plays a role in the prevention of damage for IR the deletion of the genes in the axis in mice should result in the creation of new murine models for the investigation of human illness, including human malignancies, that have a strong genetic connection to aging or the genes in the CLOCK/NAD+/SIRT3 axis. In this regard, our preliminary results suggest that circadian CLOCK proteins coordinate mitochondrial metabolism, in part via the modulation of protein acetylation, including MnSOD, to metabolic and oxidative pathways with circadian rhythms. Based on our results, and those or others, it is hypothesized that the CLOCK/NAD+/SIRT3 signaling axis protects against IR-induced damage, cytotoxicity, genomic instability, and carcinogenesis, through the regulation of MnSOD mitochondrial detoxification activity via deacetylation of K68 and K122. In addition, it is proposed that this axis is a potentil molecular axis to sensitize tumor cells to cytotoxic strategies, including IR.
描述(由适用提供):个性化癌症治疗的一种想法是确定将受益于特定治疗策略的癌症患者的特定亚组。最近,NCI提出了一种新的研究重点,以设计严格而创新的研究策略,以解决癌症研究中的特定问题和悖论。这项研究提案解决了NCI的重点:那就是直接寿命的蛋白质至少在某些部分如何影响癌症发展的分子机制。另外,可以对直接衰老的机制有更深入的了解来增强癌症的预防和/或治疗?在这方面,建议时钟/NAD+/SIRT3轴在预防IR的损害中发挥作用,在小鼠中删除轴的基因应该导致创建新的小鼠模型,以研究人类疾病,包括人类恶性肿瘤,这些模型在包括与衰老的基因或基因之间具有强烈的遗传或nAD/nAD/nAD+/nAD+/sipt+/sipt 3轴的基因相关。在这方面,我们的初步结果表明,昼夜节律蛋白质坐标的线粒体代谢部分是通过蛋白质乙酰化的调节(包括MNSOD)的调节,以昼夜节律的方式对代谢和氧化途径进行调节。根据我们的结果以及那些或其他的结果,可以假设通过MNSOD线粒体解毒活性通过K68和K68和K122的deacetylation来调节,时钟/NAD/NAD+/SIRT3信号轴可防止IR诱导的损伤,细胞毒性,基因组不稳定性和致癌作用。另外,有人提出该轴是一种潜在的分子轴,可以将肿瘤细胞感知到包括IR在内的细胞毒性策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
David Gius的其他基金
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:1073781010737810
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:1053347210533472
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:1039045110390451
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
- 批准号:1032733610327336
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
- 批准号:1054119310541193
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:1054883510548835
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:1033542410335424
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性。
- 批准号:1081755610817556
- 财政年份:2021
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:1002496410024964
- 财政年份:2017
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:98890669889066
- 财政年份:2017
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
相似国自然基金
仙茅酚苷类成分靶向组蛋白去乙酰化酶HDAC1抑制BMSC衰老防治老年性骨质疏松的机制
- 批准号:82304806
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
丁酸上调HSD11b2乙酰化抑制HPA轴激活改善孤独症样社交障碍机制研究
- 批准号:82372559
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
ACSS2介导的乙酰辅酶a合成在巨噬细胞组蛋白乙酰化及急性肺损伤发病中的作用机制研究
- 批准号:82370084
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
高糖水平通过JUN乙酰化修饰上调NCAPD3促进结直肠癌发生的分子机制
- 批准号:82303250
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
芪苓温肾消囊颗粒通过HDAC5调控GATA1启动子区H3K27乙酰化改善PCOS妊娠早期流产的机制研究
- 批准号:82374498
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
- 批准号:1072676310726763
- 财政年份:2023
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:1072726810727268
- 财政年份:2023
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease
保留大脑 NAD 作为阿尔茨海默病的一种新型非淀粉样蛋白治疗策略
- 批准号:1058841410588414
- 财政年份:2023
- 资助金额:$ 36.13万$ 36.13万
- 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:1060088710600887
- 财政年份:2023
- 资助金额:$ 36.13万$ 36.13万
- 项目类别: